AUSTIN, Texas--(BUSINESS WIRE)--Study results from Introgen Therapeutics, Inc.’s (NASDAQ:INGN) phase III ADVEXIN® (p53 tumor suppressor therapy) clinical trial were presented as a late-breaking, oral presentation earlier today at the American Society for Gene Therapy (ASGT) annual meeting in Boston, Mass. To access the ASGT presentation on Introgen’s web site please visit the Events page at www.introgen.com. The results demonstrate that ADVEXIN has significantly increased survival in end-stage head and neck cancer patients.
